Sharing an email I received. There are not enough webinars on risk assessments and control strategies. It looks like the path forward to register is via email, Jason.dabhi@treffenmedia.com.
There have been a number of product recalls specifically related to nitrosamine impurities reinstating the fact nitrosamines continues to be a leading problem for the pharma industry. Understanding the need for recent and relevant updates on the topic of Nitrosamines we are organising “Nitrosamine Virtual Workshop” scheduled on 7th March 2025.
Time (EST)- 10:00 am to 12:45 pm
Workshop Leader - Dr. Andrew Teasdale , Senior Principal Scientist, AstraZeneca, UK
Andrew Teasdale PhD has 30 years’ experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. In his current role he chairs AstraZeneca’s Impurity Advisory Group With over 50 scientific papers, he has also written 3 books:
· Genotoxic Impurities – Strategies for Identification and control
· ICH Quality Guidelines – An Implementation Guide.
· Mutagenic Impurities – Strategies for Identification and Control Second Edition.
Key Topics Covered:
- Effective management of API and Drug Product – risk assessment and practical control.
- Current safety perspective relating to N-Nitrosamines and the idealised future position.
- Where the challenges remain and what is achievable
Pricing
| Register for 1 participant | USD 350 |
|---|---|
| Register for 2 participant | USD 500 |
| Register for 3 or more | USD 199 Per participant |
Please let me know if you wish to register/nominate your team members.
We look forward to hearing from you.
Kind regards,
Jason Dabhi
+91 8849097588